Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 185

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Calcium Dyshomeostasis in Alzheimer’s Disease Pathogenesis

Open access
Cascella, Roberta, Cecchi, Cristina · 2021 · International Journal of Molecular Sciences

Abstract

Alzheimer’s disease (AD) is the most common age-related neurodegenerative disorder that is characterized by amyloid β-protein deposition in senile plaques, neurofibrillary tangles consisting of abnormally phosphorylated tau protein, and neuronal loss leading to cognitive decline and dementia. Despite extensive research, the exact mechanisms underlying AD remain unknown and effective treatment is not available. Many hypotheses have been proposed to explain AD pathophysiology; however, there is general consensus that the abnormal aggregation of the amyloid β peptide (Aβ) is the initial event triggering a pathogenic cascade of degenerating events in cholinergic neurons. The dysregulation of calcium homeostasis has been studied considerably to clarify the mechanisms of neurodegeneration induced by Aβ. Intracellular calcium acts as a second messenger and plays a key role in the regulation of neuronal functions, such as neural growth and differentiation, action potential, and synaptic plasticity. The calcium hypothesis of AD posits that activation of the amyloidogenic pathway affects neuronal Ca2+ homeostasis and the mechanisms responsible for learning and memory. Aβ can disrupt Ca2+ signaling through several mechanisms, by increasing the influx of Ca2+ from the extracellular space and by activating its release from intracellular stores. Here, we review the different molecular mechanisms and receptors involved in calcium dysregulation in AD and possible therapeutic strategies for improving the treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms22094914

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 173

  1. Brookmeyer, 2007, Forecasting the global burden of Alzheimer’s disease, Alzheimers Dement., 3, 186, 10.1016/j.jalz.2007.04.381 · DOI · Paper page
  2. Elahi, 2017, A clinicopathological approach to the diagnosis of dementia, Nat. Rev. Neurol., 13, 457, 10.1038/nrneurol.2017.96 · DOI · Paper page
  3. Cacabelos, 2007, Donepezil in Alzheimer’s disease: From conventional trials to pharmacogenetics, Neuropsychiatr. Dis. Treat., 3, 303
  4. Olin, J.T., and Schneider, L. (2002). Galantamine for Alzheimer’s disease. Cochrane Database Syst. Rev. · DOI
  5. Hampel, 2019, Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer’s disease, Dialogues Clin. Neurosci., 21, 177, 10.31887/DCNS.2019.21.2/hhampel · DOI
  6. Iqbal, 1984, Alzheimer paired helical filaments: Immunochemical identification of polypeptides, Acta Neuropathol., 62, 259, 10.1007/BF00687607 · DOI
  7. Steinman, 2021, Microvascular alterations in Alzheimer’s disease, Front. Cell. Neurosci., 14, 618986, 10.3389/fncel.2020.618986 · DOI
  8. Olsson, 2016, CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: A systematic review and meta-analysis, Lancet Neurol., 15, 673, 10.1016/S1474-4422(16)00070-3 · DOI · Paper page
  9. Lista, 2017, Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer’s disease, Expert Rev. Neurother., 17, 47, 10.1080/14737175.2016.1204234 · DOI
  10. Baldacci, 2017, Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer’s disease and other neurodegenerative diseases, Expert Rev. Proteom., 14, 285, 10.1080/14789450.2017.1304217 · DOI · Paper page
  11. Tong, 2014, Brain metabolic dysfunction at the core of Alzheimer’s disease, Biochem. Pharmacol., 88, 548, 10.1016/j.bcp.2013.12.012 · DOI · Paper page
  12. Hardy, 2002, The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994 · DOI · Paper page
  13. Watts, 2017, β-Amyloid Prions and the Pathobiology of Alzheimer’s Disease, Cold Spring Harb. Perspect. Biol., 8, a023507, 10.1101/cshperspect.a023507 · DOI
  14. Barber, R.C. (2012). The Genetics of Alzheimer’s Disease. Scientifica, 246210. · DOI
  15. Liu, 2019, Enriched gestation activates the IGF pathway to evoke embryo-adult benefits to prevent Alzheimer’s disease, Transl. Neurodegener., 8, 8, 10.1186/s40035-019-0149-9 · DOI
  16. Lambert, 2011, Genetics of Alzheimer’s disease: New evidences for an old hypothesis?, Curr. Opin. Genet. Dev., 21, 295, 10.1016/j.gde.2011.02.002 · DOI
  17. Guo, 2019, Elevation of pS262-tau and Demethylated PP2A in retina occurs earlier than in Hippocampus during Hyperhomocysteinemia, J. Alzheimers Dis., 68, 367, 10.3233/JAD-180978 · DOI
  18. Xu, 2016, Biomarkers for early diagnostic of mild cognitive impairment in Type-2 diabetes patients: A multicentre, retrospective, Nested Case-Control Study, EBioMedicine, 5, 105, 10.1016/j.ebiom.2016.02.014 · DOI
  19. Zhang, 2019, Liraglutide ameliorates hyperhomocysteinemia-induced Alzheimer-like pathology and memory deficits in rats via multi-molecular targeting, Neurosci. Bull., 35, 724, 10.1007/s12264-018-00336-7 · DOI
  20. Thinakaran, 2008, Amyloid precursor protein trafficking, processing, and function, J. Biol. Chem., 283, 29615, 10.1074/jbc.R800019200 · DOI · Paper page
  21. Li, 2000, Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1, Nature, 405, 689, 10.1038/35015085 · DOI · Paper page
  22. Duff, 1996, Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1, Nature, 383, 710, 10.1038/383710a0 · DOI · Paper page
  23. Borchelt, 1996, Familial Alzheimer’s disease-linked presenilin 1 variants elevate Aβ1–42/1–40 ratio in vitro and in vivo, Neuron, 17, 1005, 10.1016/S0896-6273(00)80230-5 · DOI · Paper page
  24. Kanatsu, 2014, Decreased CALM expression reduces Aβ42 to total Aβ ratio through clathrin-mediated endocytosis of γ-secretase, Nat. Commun., 5, 3386, 10.1038/ncomms4386 · DOI
  25. Bitan, 2003, Amyloid beta-protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways, Proc. Natl. Acad. Sci. USA, 100, 330, 10.1073/pnas.222681699 · DOI · Paper page
  26. Roychaudhuri, 2009, Amyloid β-Protein Assembly and Alzheimer Disease, J. Biol. Chem., 284, 4749, 10.1074/jbc.R800036200 · DOI · Paper page
  27. Gao, 2018, Tau in Alzheimer’s disease: Mechanisms and therapeutic strategies, Curr. Alzheimer Res., 15, 283, 10.2174/1567205014666170417111859 · DOI · Paper page
  28. Guo, 2017, Roles of tau protein in health and disease, Acta Neuropathol., 133, 665, 10.1007/s00401-017-1707-9 · DOI · Paper page
  29. Alonso, 2001, Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments, Proc. Natl. Acad. Sci. USA, 98, 6923, 10.1073/pnas.121119298 · DOI · Paper page
  30. Iqbal, 2010, Tau in Alzheimer disease and related tauopathies, Curr. Alzheimer Res., 7, 656, 10.2174/156720510793611592 · DOI · Paper page
  31. Sowade, 2017, Seed-induced acceleration of amyloid-betamediated neurotoxicity in vivo, Nat. Commun., 8, 512, 10.1038/s41467-017-00579-4 · DOI
  32. Hardy, 2006, Has the amyloid cascade hypothesis for Alzheimer’s disease been proved?, Curr. Alzheimer Res., 3, 71, 10.2174/156720506775697098 · DOI · Paper page
  33. Buccafusco, J.J. (2009). Transgenic mouse models of Alzheimer’s disease: Behavioral testing and considerations. Methods of Behavior Analysis in Neuroscience, CRC Press. [2nd ed.].
  34. Walsh, 2004, Oligomers on the brain: The emerging role of soluble protein aggregates in neurodegeneration, Protein Pept. Lett., 11, 213, 10.2174/0929866043407174 · DOI · Paper page
  35. Selkoe, 2008, Biochemistry and molecular biology of amyloid β-protein and the mechanism of Alzheimer’s disease, Handb. Clin. Neurol., 89, 245, 10.1016/S0072-9752(07)01223-7 · DOI · Paper page
  36. Irvine, 2008, Protein aggregation in the brain: The molecular basis for Alzheimer’s and Parkinson’s diseases, Mol. Med., 14, 451, 10.2119/2007-00100.Irvine · DOI · Paper page
  37. Busche, 2012, Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer’s disease, Proc. Natl. Acad. Sci. USA, 109, 8740, 10.1073/pnas.1206171109 · DOI · Paper page
  38. Hudry, 2017, Soluble oligomeric amyloid-β induces calcium dyshomeostasis that precedes synapse loss in the living mouse brain, Mol. Neurodegener., 12, 27, 10.1186/s13024-017-0169-9 · DOI · Paper page
  39. Ferreira, 2015, Aβ and NMDAR activation cause mitochondrial dysfunction involving ER calcium release, Neurobiol. Aging, 36, 680, 10.1016/j.neurobiolaging.2014.09.006 · DOI
  40. Kayed, 2013, Molecular Mechanism of amyloid Oligomers Toxicity, J. Alzheimers Dis., 33, S67, 10.3233/JAD-2012-129001 · DOI · Paper page
  41. Cecchi, 2013, The amyloid-cell membrane system. The interplay between the biophysical features of oligomers/fibrils and cell membrane defines amyloid toxicity, Biophys. Chem., 182, 30, 10.1016/j.bpc.2013.06.003 · DOI
  42. Zampagni, 2010, Lipid rafts are primary mediators of amyloid oxidative attack on plasma membrane, J. Mol. Med., 88, 597, 10.1007/s00109-010-0603-8 · DOI
  43. Evangelisti, 2016, Binding affinity of amyloid oligomers to cellular membranes is a generic indicator of cellular dysfunction in protein misfolding diseases, Sci. Rep., 6, 32721, 10.1038/srep32721 · DOI
  44. Bigi, 2020, Targeting pathological amyloid aggregates with conformation-sensitive antibodies, Curr. Alzheimer Res., 17, 722, 10.2174/1567205017666201109093848 · DOI
  45. Cecchi, 1999, Glutathione level is altered in lymphoblasts from patients with familial Alzheimer’s disease, Neurosci. Lett., 275, 152, 10.1016/S0304-3940(99)00751-X · DOI · Paper page
  46. Pensalfini, 2008, Protective effect of new S-acylglutathione derivatives against amyloid-induced oxidative stress, Free Rad. Biol. Med., 44, 1624, 10.1016/j.freeradbiomed.2008.01.025 · DOI
  47. Pensalfini, 2011, Membrane cholesterol enrichment prevents Aβ-induced oxidative stress in Alzheimer’s fibroblasts, Neurobiol. Aging, 32, 210, 10.1016/j.neurobiolaging.2009.02.010 · DOI
  48. Cenini, 2010, Generation of reactive oxygen species by beta amyloid fibrils and oligomers involves different intra/extracellular pathways, Amino Acids, 38, 1101, 10.1007/s00726-009-0339-3 · DOI
  49. Zampagni, 2012, Novel S-acyl glutathione derivatives prevent amyloid oxidative stress and cholinergic dysfunction in Alzheimer disease models, Free Radic. Biol. Med., 52, 1362, 10.1016/j.freeradbiomed.2012.01.012 · DOI
  50. Cascella, 2014, S-linolenoyl glutathione intake extends life-span and stress resistance via Sir-2.1 upregulation in Caenorhabditis elegans, Free Radic. Biol. Med., 73, 127, 10.1016/j.freeradbiomed.2014.05.004 · DOI
  51. Jackson, 2016, Cellular proteostasis: Degradation of misfolded proteins by lysosomes, Essay Biochem., 60, 173, 10.1042/EBC20160005 · DOI
  52. Höhn, A., Tramutola, A., and Cascella, R. (2020). Proteostasis Failure in Neurodegenerative Diseases: Focus on Oxidative Stress. Oxid. Med. Cell. Longev., 5497046. · DOI · Paper page
  53. Salminen, 2013, Impaired autophagy and APP processing in Alzheimer’s disease: The potential role of Beclin 1 interactome, Prog. Neurobiol., 106–107, 33, 10.1016/j.pneurobio.2013.06.002 · DOI · Paper page
  54. Lobello, 2012, Targeting Beta amyloid: A clinical review of immunotherapeutic approaches in Alzheimer’s disease, Int. J. Alzheimers Dis., 2012, 628070
  55. Cascella, 2013, Extracellular chaperones prevent Aβ42-induced toxicity in rat brains, Biochim. Biophys. Acta, 1832, 1217, 10.1016/j.bbadis.2013.04.012 · DOI
  56. Bennett, 2017, Enhanced tau aggregation in the presence of amyloid β, Am. J. Pathol., 187, 1601, 10.1016/j.ajpath.2017.03.011 · DOI · Paper page
  57. Hanseeuw, 2019, Association of amyloid and tau with cognition in preclinical Alzheimer disease: A longitudinal study, JAMA Neurol., 76, 915, 10.1001/jamaneurol.2019.1424 · DOI · Paper page
  58. Timmers, 2019, Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer’s disease, Neurobiol. Aging, 79, 131, 10.1016/j.neurobiolaging.2019.03.016 · DOI
  59. Majdi, 2020, Amyloid- β, tau, and the cholinergic system in Alzheimer’s disease: Seeking direction in a tangle of clues, Rev. Neurosci., 31, 391, 10.1515/revneuro-2019-0089 · DOI
  60. Lynch, 1989, Links between long-term potentiation and neuropathology. An hypothesis involving calcium-activated proteases, Ann. N. Y. Acad. Sci., 568, 171, 10.1111/j.1749-6632.1989.tb12505.x · DOI
  61. Briggs, 2017, Emerging pathways driving early synaptic pathology in Alzheimer’s disease, Biochem. Biophys. Res. Commun., 19, 988, 10.1016/j.bbrc.2016.09.088 · DOI
  62. Pchitskaya, 2018, Calcium signaling and molecular mechanisms underlying neurodegenerative diseases, Cell Calcium, 70, 87, 10.1016/j.ceca.2017.06.008 · DOI · Paper page
  63. Zampese, 2012, Intracellular organelles in the saga of Ca2+ homeostasis: Different molecules for dierent purposes?, Cell. Mol. Life Sci., 69, 1077, 10.1007/s00018-011-0845-9 · DOI
  64. Supnet, 2010, The dysregulation of intracellular calcium in Alzheimer disease, Cell Calcium, 47, 183, 10.1016/j.ceca.2009.12.014 · DOI · Paper page
  65. LaFerla, 2002, Calcium dyshomeostasis and intracellular signalling in Alzheimer’s disease, Nat. Rev. Neurosci., 3, 862, 10.1038/nrn960 · DOI · Paper page
  66. Green, 2008, Linking calcium to Abeta and Alzheimer’s disease, Neuron, 59, 190, 10.1016/j.neuron.2008.07.013 · DOI · Paper page
  67. Mark, 1995, Amyloid beta-peptide impairs ion-motive ATPase activities: Evidence for a role in loss of neuronal Ca2+ homeostasis and cell death, J. Neurosci., 15, 6239, 10.1523/JNEUROSCI.15-09-06239.1995 · DOI · Paper page
  68. Santos, 2010, Network excitability dysfunction in Alzheimer’s disease: Insights from in vitro and in vivo models, Rev. Neurosci., 21, 153
  69. Berridge, 1998, Neuronal calcium signaling, Neuron, 2, 13, 10.1016/S0896-6273(00)80510-3 · DOI · Paper page
  70. Kang, 2001, An important role of neural activity-dependent CaMKIV signaling in the consolidation of long-term memory, Cell, 106, 771, 10.1016/S0092-8674(01)00497-4 · DOI · Paper page
  71. Burgoyne, 2019, Calcium sensors in neuronal function and dysfunction, Cold Spring Harb. Perspect. Biol., 11, a035154, 10.1101/cshperspect.a035154 · DOI
  72. Wang, 2017, Calcium Dysregulation in Alzheimer’s Disease: A Target for New Drug Development, J. Alzheimers Dis. Parkinsonism, 7, 374, 10.4172/2161-0460.1000374 · DOI
  73. Prole, 2019, Structure and function of ip3 receptors, Cold Spring Harb. Perspect. Biol., 11, a035063, 10.1101/cshperspect.a035063 · DOI · Paper page
  74. Santulli, 2017, Intracellular calcium release channels: An update, J. Physiol., 595, 3041, 10.1113/JP272781 · DOI · Paper page
  75. Krebs, 2015, Ca2+ homeostasis and endoplasmic reticulum (ER) stress: An integrated view of calcium signaling, Biochem. Biophys. Res. Commun., 460, 114, 10.1016/j.bbrc.2015.02.004 · DOI · Paper page
  76. Putney, 2017, The functions of store-operated calcium channels, Biochim. Biophys. Acta Mol. Cell Res., 1864, 900, 10.1016/j.bbamcr.2016.11.028 · DOI
  77. Prakriya, 2015, Store-operated calcium channels, Physiol. Rev., 95, 1383, 10.1152/physrev.00020.2014 · DOI · Paper page
  78. Staord, 2017, The plasma membrane calcium ATPases and their role as major new players in human disease, Physiol. Rev., 97, 1089, 10.1152/physrev.00028.2016 · DOI
  79. DiPolo, 2006, Sodium/calcium exchanger: Influence of metabolic regulation on ion carrier interactions, Physiol. Rev., 86, 155, 10.1152/physrev.00018.2005 · DOI · Paper page
  80. Baughman, 2011, Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter, Nature, 476, 341, 10.1038/nature10234 · DOI · Paper page
  81. Raffaello, 2011, A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter, Nature, 476, 336, 10.1038/nature10230 · DOI · Paper page
  82. Palty, 2010, NCLX is an essential component of mitochondrial Na+/Ca2+ exchange, Proc. Natl. Acad. Sci. USA, 107, 436, 10.1073/pnas.0908099107 · DOI · Paper page
  83. Jiang, 2009, Genome-wide RNAi screen identifies Letm1 as a mitochondrial Ca2+/H+ antiporter, Science, 326, 144, 10.1126/science.1175145 · DOI · Paper page
  84. Bronner, 2001, Extracellular and intracellular regulation of calcium homeostasis, Sci. World J., 1, 919, 10.1100/tsw.2001.489 · DOI
  85. Vance, 2014, MAM (mitochondria-associated membranes) in mammalian cells: Lipids and beyond, Biochim. Biophys. Acta, 1841, 4
  86. Hayashi, 2010, Cholesterol at the endoplasmic reticulum: Roles of the sigma-1 receptor chaperone and implications thereof in human diseases, Subcell. Biochem., 51, 381, 10.1007/978-90-481-8622-8_13 · DOI
  87. Pinton, 2018, Mitochondria-associated membranes (MAMs) and pathologies editorial, Cell Death Dis., 9, 413, 10.1038/s41419-018-0424-1 · DOI
  88. Khachaturian, 1989, Calcium, membranes, aging, and Alzheimer’s disease. Introduction and overview, Ann. N. Y. Acad. Sci., 568, 1, 10.1111/j.1749-6632.1989.tb12485.x · DOI · Paper page
  89. Landfield, 1984, Prolonged Ca2+-dependent after hyperpolarizations in hippocampal neurons of aged rats, Science, 226, 1, 10.1126/science.6494926 · DOI · Paper page
  90. Landfield, 1987, Increased calcium current’ hypothesis of brain aging, Neurobiol. Aging, 8, 346, 10.1016/0197-4580(87)90074-1 · DOI · Paper page
  91. Verkhratsky, 1998, Calcium and neuronal ageing, Trends Neurosci., 21, 2, 10.1016/S0166-2236(97)01156-9 · DOI · Paper page
  92. Toescu, 2004, Ca2+ regulation and gene expression in normal brain aging, Trends Neurosci., 27, 614, 10.1016/j.tins.2004.07.010 · DOI · Paper page
  93. Toescu, 2007, The importance of being subtle: Small changes in calcium homeostasis control cognitive decline in normal aging, Aging Cell, 6, 267, 10.1111/j.1474-9726.2007.00296.x · DOI · Paper page
  94. Foster, 2007, Calcium homeostasis and modulation of synaptic plasticity in the aged brain, Aging Cell, 6, 319, 10.1111/j.1474-9726.2007.00283.x · DOI · Paper page
  95. Bezprozvanny, 2009, Calcium signaling and neurodegenerative diseases, Trends Mol. Med., 15, 89, 10.1016/j.molmed.2009.01.001 · DOI · Paper page
  96. Querfurth, 1994, Calcium ionophore increases amyloid β peptide production by cultured cells, Biochemistry, 33, 4550, 10.1021/bi00181a016 · DOI · Paper page
  97. Bezprozvanny, 2008, Neuronal calcium mishandling and the pathogenesis of Alzheimer’s disease, Trends Neurosci., 31, 454, 10.1016/j.tins.2008.06.005 · DOI · Paper page
  98. Etcheberrigaray, 1998, Calcium responses in fibroblasts from asymptomatic members of Alzheimer’s disease families, Neurobiol. Dis., 5, 37, 10.1006/nbdi.1998.0176 · DOI
  99. Latulippe, J., and Lotito, D. (2018). A mathematical model for the effects of amyloid beta on intracellular calcium. PLoS ONE, 13. · DOI
  100. Demuro, 2005, Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers, J. Biol. Chem., 280, 17294, 10.1074/jbc.M500997200 · DOI · Paper page
  101. Evangelisti, 2012, Membrane lipid composition and its physicochemical properties define cell vulnerability to aberrant protein oligomers, J. Cell Sci., 125, 2416
  102. Limbocker, 2019, Trodusquemine enhances Aβ42 aggregation but suppresses its toxicity by displacing oligomers from cell membranes, Nat. Commun., 10, 225, 10.1038/s41467-018-07699-5 · DOI
  103. Limbocker, 2020, Trodusquemine displaces protein misfolded oligomers from cell membranes and abrogates their cytotoxicity through a generic mechanism, Commun. Biol., 3, 435, 10.1038/s42003-020-01140-8 · DOI
  104. Evangelisti, 2013, Lipid rafts mediate amyloid-induced calcium dyshomeostasis and oxidative stress in Alzheimer’s disease, Curr. Alzheimer Res., 10, 143, 10.2174/1567205011310020004 · DOI
  105. Ladiwala, 2012, Conformational differences between two amyloid beta oligomers of similar size and dissimilar toxicity, J. Biol. Chem., 287, 24765, 10.1074/jbc.M111.329763 · DOI · Paper page
  106. Contrusciere, 2010, Lipid raft disruption protects mature neurons against amyloid oligomer toxicity, Biochim. Biophys. Acta, 1802, 406, 10.1016/j.bbadis.2010.01.007 · DOI
  107. Cascella, 2017, Soluble oligomers require a ganglioside to trigger neuronal calcium overload, J. Alzheimers Dis., 60, 923, 10.3233/JAD-170340 · DOI
  108. Schengrund, 2010, Lipid rafts: Keys to neurodegeneration, Brain Res. Bull., 82, 7, 10.1016/j.brainresbull.2010.02.013 · DOI
  109. Gunther, 2012, Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons, Nat. Neurosci., 15, 1227, 10.1038/nn.3178 · DOI · Paper page
  110. Calamai, 2016, Single molecule experiments emphasize GM1 as a key player of the different cytotoxicity of structurally distinct Aβ1-42 oligomers, Biochim. Biophys. Acta, 1858, 386, 10.1016/j.bbamem.2015.12.009 · DOI
  111. Fonseca, 2015, Amyloid-beta disrupts calcium and redox homeostasis in brain endothelial cells, Mol. Neurobiol., 51, 610, 10.1007/s12035-014-8740-7 · DOI
  112. Ranjan, B., Chong, K.H., and Zheng, J. (2018). Composite mathematical modeling of calcium signaling behind neuronal cell death in Alzheimer’s disease. BMC Syst. Biol., 12. · DOI
  113. Yang, 2009, Amyloid precursor protein regulates Cav1.2 L-type calcium channel levels and function to influence GABAergic short-term plasticity, J. Neurosci., 29, 15660, 10.1523/JNEUROSCI.4104-09.2009 · DOI
  114. Arispe, 1993, Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: Blockade by tromethamine and aluminum, Proc. Natl. Acad. Sci. USA, 90, 567, 10.1073/pnas.90.2.567 · DOI · Paper page
  115. Bhatia, 2000, Fresh and globular amyloid beta protein (1–42) induces rapid cellular degeneration: Evidence for Abeta P channel-mediated cellular toxicity, FASEB J., 14, 1233, 10.1096/fasebj.14.9.1233 · DOI · Paper page
  116. Kagan, 2002, The channel hypothesis of Alzheimer’s disease: Current status, Peptides, 23, 1311, 10.1016/S0196-9781(02)00067-0 · DOI · Paper page
  117. Arispe, 2007, Abeta ion channels. Prospects for treating Alzheimer’s disease with Abeta channel blockers, Biochim. Biophys. Acta, 1768, 1952, 10.1016/j.bbamem.2007.03.014 · DOI · Paper page
  118. Sokolov, 2006, Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure, J. Gen. Physiol., 128, 637, 10.1085/jgp.200609533 · DOI · Paper page
  119. Samad, 2017, Calcium Regulation in Alzheimer’s Disease: Mechanistic Understanding, J. Coll. Physicians Surg. Pak., 27, 566
  120. Reese, 2011, A role for calcineurin in Alzheimer’s disease, Curr. Neuropharmacol., 9, 685, 10.2174/157015911798376316 · DOI
  121. Yin, 2016, Tau accumulation induces synaptic impairment and memory deficit by calcineurin-mediated inactivation of nuclear CaMKIV/CREB signaling, Proc. Natl. Acad. Sci. USA, 113, E3773, 10.1073/pnas.1604519113 · DOI · Paper page
  122. Cavallucci, 2013, Calcineurin inhibition rescues early synaptic plasticity deficits in a mouse model of Alzheimer’s disease, NeuroMol. Med., 15, 541, 10.1007/s12017-013-8241-2 · DOI
  123. Lin, 2018, Endoplasmic reticulum stress induces spatial memory deficits by activating GSK-3, J. Cell. Mol. Med., 22, 3489, 10.1111/jcmm.13626 · DOI
  124. Liu, 2016, SIL1 rescued bip elevation-related tau hyperphosphorylation in ER stress, Mol. Neurobiol., 53, 983, 10.1007/s12035-014-9039-4 · DOI
  125. Zhang, 2021, δ-Secretase-cleaved Tau stimulates Aβ production via upregulating STAT1-BACE1 signaling in Alzheimer’s disease, Mol. Psychiatry, 26, 586, 10.1038/s41380-018-0286-z · DOI
  126. Galla, L., Redolfi, N., Pozzan, T., Pizzo, P., and Greotti, E. (2020). Intracellular calcium dysregulation by the Alzheimer’s disease-linked protein presenilin 2. Int. J. Mol. Sci., 21. · DOI
  127. Gaspar, 1994, Sparing of the dopaminergic neurons containing calbindin-D28k and of the dopaminergic mesocortical projections in weaver mutant mice, Neuroscience, 61, 293, 10.1016/0306-4522(94)90232-1 · DOI
  128. Damier, 1999, The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease, Brain, 122, 1437, 10.1093/brain/122.8.1437 · DOI · Paper page
  129. Foehring, 2009, Endogenous calcium buffering capacity of substantia nigral dopamine neurons, J. Neurophysiol., 102, 2326, 10.1152/jn.00038.2009 · DOI
  130. Lombardo, 2015, Role of the nicotinic acetylcholine receptor in Alzheimer’s disease pathology and treatment, Neuropharmacology, 96, 255, 10.1016/j.neuropharm.2014.11.018 · DOI · Paper page
  131. Hermann, 2013, Synthetic Aβ oligomers (Aβ1-42 globulomer) modulate presynaptic calcium currents: Prevention of Aβ-induced synaptic deficits by calcium channel blockers, Eur. J. Pharmacol., 702, 44, 10.1016/j.ejphar.2013.01.030 · DOI
  132. Ueda, 1997, Amyloid beta protein potentiates Ca2+ influx through L-type voltage-sensitive Ca2+ channels: A possible involvement of free radicals, J. Neurochem., 68, 265, 10.1046/j.1471-4159.1997.68010265.x · DOI · Paper page
  133. Willis, 2010, L-type calcium channel CaV 1.2 in transgenic mice overexpressing human AbetaPP751 with the London (V717I) and Swedish (K670M/N671L) mutations, J. Alzheimers Dis., 20, 1167, 10.3233/JAD-2010-091117 · DOI
  134. Kim, 2011, Effects of amyloid-β peptides on voltage-gated L-type Ca(V)1.2 and Ca(V)1.3 Ca(2+) channels, Mol. Cells, 32, 289, 10.1007/s10059-011-0075-x · DOI
  135. Kelly, 2006, Beta-Amyloid-induced dynamin 1 degradation is mediated by N-methyl-D-aspartate receptors in hippocampal neurons, J. Biol. Chem., 281, 28079, 10.1074/jbc.M605081200 · DOI · Paper page
  136. Beitz, 1997, The inhibitory effects of beta-amyloid on glutamate and glucose uptakes by cultured astrocytes, Brain Res., 754, 65, 10.1016/S0006-8993(97)00043-7 · DOI
  137. Brera, 2004, Beta-amyloid25–35 inhibits glutamate uptake in cultured neurons and astrocytes: Modulation of uptake as a survival mechanism, Neurobiol. Dis., 15, 580, 10.1016/j.nbd.2003.12.006 · DOI
  138. Kervern, 2012, Selective impairment of some forms of synaptic plasticity by oligomeric amyloid-β peptide in the mouse hippocampus: Implication of extrasynaptic NMDA receptors, J. Alzheimers Dis., 32, 183, 10.3233/JAD-2012-120394 · DOI
  139. Fani, 2021, Aβ Oligomers Dysregulate Calcium Homeostasis by Mechanosensitive Activation of AMPA and NMDA Receptors, ACS Chem. Neurosci., 12, 766, 10.1021/acschemneuro.0c00811 · DOI
  140. Ferreira, 2012, Amyloid beta peptide 1–42 disturbs intracellular calcium homeostasis through activation of GluN2B-containing N-methyl-d-aspartate receptors in cortical cultures, Cell Calcium, 51, 95, 10.1016/j.ceca.2011.11.008 · DOI · Paper page
  141. Costa, 2012, Amyloid β-induced ER stress is enhanced under mitochondrial dysfunction conditions, Neurobiol. Aging, 33, 824.e5, 10.1016/j.neurobiolaging.2011.04.011 · DOI
  142. Ferreira, 2015, Soluble amyloid-βoligomers as synaptotoxins leading to cognitive impairment in Alzheimer’s disease, Front. Cell. Neurosci., 26, 191
  143. Nomura, 2005, Mechanism of impairment of long-term potentiation by amyloid β is independent of NMDA receptors or voltage-dependent calcium channels in hippocampal CA1 pyramidal neurons, Neurosci. Lett., 391, 1, 10.1016/j.neulet.2005.08.024 · DOI
  144. Liu, 2012, Mitochondrial outer-membrane protein FUNDC1 mediates hypoxia-induced mitophagy in mammalian cells, Nat. Cell Biol., 14, 177, 10.1038/ncb2422 · DOI · Paper page
  145. Bezprozvanny, 2013, The synaptic maintenance problem: Membrane recycling, Ca2+ homeostasis and late onset degeneration, Mol. Neurodegener., 8, 23, 10.1186/1750-1326-8-23 · DOI
  146. Francis, 2008, Glutamatergic approaches to the treatment of cognitive and behavioural symptoms of Alzheimer’s disease, Neurodegener. Dis., 5, 241, 10.1159/000113713 · DOI
  147. Mota, 2012, Amyloid-beta peptide1–42 causes microtubule deregulation through N-methyl-D-aspartate receptors in mature hippocampal cultures, Curr. Alzheimer Res., 9, 844, 10.2174/156720512802455322 · DOI
  148. Paschen, 2003, Endoplasmic reticulum: A primary target in various acute disorders and degenerative diseases of the brain, Cell Calcium, 34, 365, 10.1016/S0143-4160(03)00139-8 · DOI · Paper page
  149. Verkhratsky, 2002, The endoplasmic reticulum and neuronal calcium signaling, Cell Calcium, 32, 393, 10.1016/S0143416002001896 · DOI · Paper page
  150. Chakroborty, 2009, Deviant ryanodine receptor-mediated calcium release resets synaptic homeostasis in presymptomatic3xTg-AD mice, J. Neurosci., 29, 9458, 10.1523/JNEUROSCI.2047-09.2009 · DOI · Paper page
  151. Ferreiro, 2004, Involvement of endoplasmic reticulum Ca2+ release through ryanodine and inositol 1,4,5-triphosphate receptors in the neurotoxic effects induced by the amyloid-beta peptide, J. Neurosci. Res., 76, 872, 10.1002/jnr.20135 · DOI
  152. Ferreiro, 2006, An endoplasmicreticulum-specific apoptotic pathway is involved in prion and amyloid-beta peptides neurotoxicity, Neurobiol. Dis., 23, 669, 10.1016/j.nbd.2006.05.011 · DOI · Paper page
  153. Supnet, 2006, Amyloid-beta-(1–42) increases ryanodine receptor-3 expression and function in neurons of TgCRND8 mice, J. Biol. Chem., 281, 38440, 10.1074/jbc.M606736200 · DOI
  154. Adasme, 2011, Amyloid β-peptide oligomers stimulate RyR-mediated Ca2+ release inducing mitochondrial fragmentation in hippocampal neurons and prevent RyR-mediated dendritic spine remodeling produced by BDNF, Antioxid. Redox Signal., 14, 1209, 10.1089/ars.2010.3287 · DOI
  155. Wang, 2019, Ca(2+) homeostasis dysregulation in Alzheimer’s disease: A focus on plasma membrane and cell organelles, FASEB J., 33, 6697, 10.1096/fj.201801751R · DOI
  156. Kelly, 1996, Amyloid beta-peptide disrupts carbachol induced muscarinic cholinergic signal transduction in control neurons, Proc. Natl. Acad. Sci. USA, 93, 6753, 10.1073/pnas.93.13.6753 · DOI · Paper page
  157. Paschen, 2001, Dependence of vital cell function on endoplasmic reticulum calcium levels: Implications for the mechanisms underlying neuronal cell injury in different pathological states, Cell Calcium, 29, 1, 10.1054/ceca.2000.0162 · DOI
  158. Pannaccione, 2012, A new concept: Aβ1-42 generates a Hyperfunctional proteolytic NCX3 fragment that delays caspase-12 activation and neuronal death, J. Neurosci., 32, 10609, 10.1523/JNEUROSCI.6429-11.2012 · DOI
  159. Ito, 1994, Internal Ca2+ mobilization is altered in fibroblasts from patients with Alzheimer disease, Proc. Natl. Acad. Sci. USA, 91, 534, 10.1073/pnas.91.2.534 · DOI · Paper page
  160. Hirashima, 1996, Calcium responses in human fibroblasts: A diagnostic molecular profile for Alzheimer’s disease, Neurobiol. Aging, 17, 549, 10.1016/0197-4580(96)00074-7 · doi:10.1016/0197-4580(96)00074-7
  161. Goldstein, 2000, The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant, Nat. Cell Biol., 2, 156, 10.1038/35004029 · DOI · Paper page
  162. Atamna, 2007, 2nd Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer’s disease, Mitochondrion, 7, 297, 10.1016/j.mito.2007.06.001 · DOI · Paper page
  163. Santos, 2010, A synergistic dysfunction of mitochondrial fission/fusion dynamics and mitophagy in Alzheimer’s disease, J. Alzheimers Dis., 20, S401, 10.3233/JAD-2010-100666 · DOI · Paper page
  164. Kopeikina, 2011, Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer’s disease brain, Am. J. Pathol., 179, 2071, 10.1016/j.ajpath.2011.07.004 · DOI · Paper page
  165. Brown, 2006, Synaptic mitochondria are more susceptible to Ca2+ overload than nonsynaptic mitochondria, J. Biol. Chem., 281, 11658, 10.1074/jbc.M510303200 · DOI · Paper page
  166. Zervas, 2005, Impaired hippocampal long-term potentiation in microtubule-associated protein 1B-deficient mice, J. Neurosci. Res., 82, 83, 10.1002/jnr.20624 · DOI
  167. Fukunaga, 1996, CaM kinase II in long-term potentiation, Neurochem. Int., 28, 343, 10.1016/0197-0186(95)00097-6 · DOI
  168. Sanz-Blasco, S., Valero, R.A., Rodriguez-Crespo, I., Villalobos, C., and Nunez, L. (2008). Mitochondrial Ca2+ overload underlies Abeta oligomers neurotoxicity providing an unexpected mechanism of neuroprotection by NSAIDs. PLoS ONE, 3. · DOI · Paper page
  169. Villalobos, 2016, Aging enables Ca2+ overload and apoptosis induced by amyloid-beta oligomers in rat hippocampal neurons: Neuroprotection by non-steroidal anti-inflammatory drugs and R-flurbiprofen in aging neurons, J. Alzheimers Dis., 54, 207, 10.3233/JAD-151189 · DOI
  170. Ferreiro, 2008, The release of calcium from the endoplasmic reticulum induced by amyloid-beta and prion peptides activates the mitochondrial apoptotic pathway, Neurobiol. Dis., 30, 331, 10.1016/j.nbd.2008.02.003 · DOI · Paper page
  171. Hou, 2020, Increased mitochondrial calcium levels associated with neuronal death in a mouse model of Alzheimer’s disease, Nat. Commun., 11, 2146, 10.1038/s41467-020-16074-2 · DOI · Paper page
  172. Supnet, 2010, Neuronal calcium signaling, mitochondrial dysfunction and Alzheimer’s disease, J. Alzheimers Dis., 20, S487, 10.3233/JAD-2010-100306 · DOI · Paper page
  173. Bonilla, 2018, A key role for MAM in mediating mitochondrial dysfunction in alzheimer disease, Cell Death Dis., 9, 335, 10.1038/s41419-017-0215-0 · DOI · Paper page

Cited by

See all 185

Metadata

Authors
Cascella, R., & Cecchi, C.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2021-05-06
Volume
22
Issue
9
Pages
4914
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3158914992
Cited by
185
References
57
FWCI
14.10
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.